Patents Assigned to University of British Columbia (UBC)
  • Methods and compositions for control of cabbage looper,
    Patent number: 9125406
    Abstract: The invention provides in part dialkoxybenzene compounds for controlling infestation by a Trichoplusia ni, and methods thereof. The compounds include a compound of Formula I: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; R2 may be at positions 2, 3 or 4 and may be H, methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; and R3 may be optionally present at positions 2, 3 and 4, and is allyl; except that when R2 is at position 2, R3 if present is at position 3, and when R2 is at position 3, R3 if present is at positions 2 or 4, and when R2 is at position 4, R3 if present is at position 2, and when R2 is at position 4 and R3, if present, has reacted with an OH group at position 1 in a Markovnikov sense, then R3 becomes R4, a dihydrofuran.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: September 8, 2015
    Assignees: Simon Fraser University, The University of British Columbia
    Inventors: Erika Plettner, Murray Bruce Isman
  • Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
    Patent number: 9101646
    Abstract: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: August 11, 2015
    Assignee: The University of British Columbia
    Inventors: Martin Gleave, Maxim Signaevsky
  • Polymers for reversing heparin-based anticoagulation
    Patent number: 9095666
    Abstract: Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: August 4, 2015
    Assignee: University of British Columbia
    Inventors: Jayachandran N. Kizhakkedathu, Rajesh A. Shenoi, Cedric J. Carter, Donald E. Brooks
  • Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
    Patent number: 9095602
    Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: August 4, 2015
    Assignee: The University of British Columbia
    Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
  • Compositions and methods for treatment of prostate and other cancers
    Patent number: 9085769
    Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 21, 2015
    Assignee: The University of British Columbia
    Inventors: Martin E. Gleave, Palma Rocchi, Maxim Signaevsky, Eliana Beraldi
  • 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
    Patent number: 9079947
    Abstract: The invention provides anti-14-3-3 eta antibodies that specifically bind to the human 14-3-3 eta protein isoform in its natural configuration while exhibiting selectivity over human 14-3-3 alpha, beta, delta, epsilon, gamma, tau, and zeta protein isoforms. Methods, kits and pharmaceutical compositions comprising said specific anti-14-3-3 eta antibodies are further provided for the diagnosis and treatment of arthritis.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: July 14, 2015
    Assignee: The University of British Columbia
    Inventor: Anthony Marotta
  • TRPM-2 antisense therapy
    Patent number: 9074209
    Abstract: A method for treating an individual suffering from a cancer comprising administering to the individual i) a chemotherapeutic agent, and ii) one antisense oligonucleotide having nucleotides in the sequence set forth in Seq. ID No. 4 and which antisense oligonucleotide has a phosphorothioate modification that increases the stability thereof in vivo, wherein the cancer expresses testosterone-repressed prostate message-2 (TRPM-2), thereby treating said individual.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: July 7, 2015
    Assignee: The University of British Columbia
    Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson
  • Systems and methods for dipole enhanced inductive power transfer
    Patent number: 9071062
    Abstract: An inductive power transfer apparatus is disclosed. A transmitter generates a first time varying magnetic field. A receiver is separated from the transmitter by a gap, but is located with the first time varying magnetic field. The receiver comprises: a conductor; and a receiver magnet located in the first time varying magnetic field and supported for movement in response to the first time varying magnetic field. The conductor and receiver are positioned relative to one another such that movement of the receiver magnet creates a second time-varying magnetic field in a vicinity of the conductor to thereby induce current in the conductor.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: June 30, 2015
    Assignee: The University of British Columbia
    Inventor: Lorne A. Whitehead
  • Combination adjuvant formulation
    Patent number: 9061001
    Abstract: Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: June 23, 2015
    Assignees: University of Saskatchewan, Dalhousie University, International Vaccines Institute, University of British Columbia
    Inventors: Sylvia van Drunen Littel-van den Hurk, Volker Gerdts, Andrew Potter, Lorne Babiuk, Robert Hancock, Scott Halperin, Jennifer Kovacs-Nolan, George Mutwiri, Song Lee, Mi-Na Kweon, Jason Kindrachuk, Melissa Elliott
  • Treatment of dissection, aneurysm, and atherosclerosis using granzyme B inhibitors
    Patent number: 9060960
    Abstract: A method of medical treatment or prevention of a vasculopathy, comprising administering a therapeutically effective amount of a granzyme B inhibitor to a subject in need thereof is provided. In other aspects uses of Granzyme B inhibitors for treatment or for preparation of medicaments for treatment of a vasculopathy are provided.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: June 23, 2015
    Assignee: The University of British Columbia
    Inventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
  • Small cationic antimicrobial peptides
    Patent number: 9017656
    Abstract: The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: April 28, 2015
    Assignee: The University of British Columbia
    Inventors: Robert E. W. Hancock, Kai Hilpert, Artem Cherkasov, Christopher Fjell
  • Enrichment of nucleic acid targets
    Patent number: 9011661
    Abstract: Methods and apparatus providing improved fidelity and specificity when separating nucleic acids from a sample, but without need for amplification. In particular, using the disclosed methods, it is possible to isolate a variant nucleic acid (i.e., a mutation) from a non-target nucleic acid (i.e., a wild-type) when the variant is present in the original sample at a much lower concentration than the non-target, e.g., 1:10,000, without substantial loss of the variant.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: April 21, 2015
    Assignees: Boreal Genomics, Inc., The University of British Columbia
    Inventors: Andrea Marziali, Nitin Sood
  • PCP2 mini-promoters
    Patent number: 9006413
    Abstract: Isolated polynucleotides comprising a PCP2 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: April 14, 2015
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra, Charles de Leeuw
  • Selective reduction of allelic variants
    Patent number: 9006198
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 14, 2015
    Assignees: Isis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • SHIP1 modulators and related methods
    Patent number: 9000050
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: April 7, 2015
    Assignee: The University of British Columbia
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Apparatus and method for processing RFID signals
    Patent number: 8994506
    Abstract: A method of processing RFID data packets at an RFID receiver includes performing channel estimation and data detection on a first received RFID data packet in a single-user reception mode, the first RFID data packet being transmitted by a first RFID tag and in response to detection of a second received RFID data packet from a second RFID tag while the first RFID data packet is being processed in the single-user reception mode, performing channel estimation and data detection in a multi-user reception mode to recover data transmitted from both the first and second RFID tags in a collision-less manner.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: March 31, 2015
    Assignee: The University of British Columbia
    Inventors: Lutz Lampe, Dana Hoffmann
  • Terpene synthases from
    Patent number: 8993284
    Abstract: An isolated nucleic acid molecule that encodes a terpene synthase and is selected from among: a) a nucleic acid molecule comprising the sequence of nucleotides set forth in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5; b) a nucleic acid molecule that is a fragment of (a); c) a nucleic acid molecule comprising a sequence of nucleotides that is complementary to (a) or (b); and d) a nucleic acid molecule that encodes a terpene synthase having at least or at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to any one of (a)-(c); wherein the nucleic acid molecule encodes a terpene synthase.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: March 31, 2015
    Assignees: The University of British Columbia, The University of Western Australia, Forest Products Commission
    Inventors: Katherine Zulak, Christopher Jones, Jessie Moniodis, Joerg Bohlmann
  • Leaching process for copper concentrates with a carbon catalyst
    Patent number: 8968442
    Abstract: A method of recovering copper from a copper sulfide concentrate comprising a copper arsenic sulfosalt or a copper antimony sulfosalt, using carbon as a catalyst. The concentrate and carbon are added to an acidic sulfate leach solution. The copper is leached from the concentrate, in the presence of an oxygen-containing gas. The operating potential is maintained above a selected level. The carbon copper sulfide ratio of the carbon being added to the copper sulfide present in the concentrate being added is at least 1:20. The carbon may be maintained above a selected concentration in the leach solution. The leached copper is recovered from the solution by conventional methods.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: March 3, 2015
    Assignee: The University of British Columbia
    Inventors: David G. Dixon, Berny Rivera-Vasquez
  • Drug delivery systems for photodynamic therapy
    Patent number: 8968715
    Abstract: The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more block copolymers. Furthermore, the invention relates to processes for the production of, and application of, said formulations and compositions as photosensitizer drug delivery systems.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: March 3, 2015
    Assignee: The University of British Columbia
    Inventors: Rubinah K. Chowdhary, David Dolphin
  • Dinuclear Indium Catalysts and Their Use for (Co)Polymerization of Cyclic Esters
    Publication number: 20150038651
    Abstract: Provided are novel dinuclear indium catalysts of formula (A) that are capable of living and immortal ring opening polymerization and copolymerization of cyclic ester monomers for the preparation of biodegradable polymers and copolymers, in particular polyesters. Also disclosed are polymerization methods and polymer products. These dinuclear indium catalysts allow less costly, highly reactive living polymerization of cyclic ester monomers with possible high turn over rates and/or substantial stereo chemical and microstructure control.
    Type: Application
    Filed: May 18, 2012
    Publication date: February 5, 2015
    Applicant: University of British Columbia
    Inventors: Parisa Mehrkhodavandi, Insun Yu, J. Alberto Acosta-Ramirez